RecruitingNot ApplicableNCT06461260

Amygdala MRI-TIS for Depression

Safety, Efficacy and Neuroimaging Mechanisms of Amygdala Temporal Interference Stimulation Therapy for Depression


Sponsor

Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University

Enrollment

30 participants

Start Date

May 27, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The study utilizes a non-invasive deep brain stimulation (temporal interference, TI) technique primarily targeting the amygdala to preliminarily explore the clinical efficacy and potential mechanisms of MRI-compatible TI technology in regulating the amygdala in depressive disorders, providing a more comprehensive basis for the application of TI technology.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study tests a non-invasive brain stimulation technique called Temporal Interference Stimulation (TIS) targeting the amygdala (a key emotional brain region) as a treatment for people with depression who have not responded well to standard antidepressant medications. **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with depression by a study physician - Your depression score on a standard scale (HAMD-17) is 17 or higher - You have not changed your antidepressant medication in the past 30 days and agree to keep it stable during the study **You may NOT be eligible if...** - You have a history of epilepsy or seizures - You have metal implants in your head or a cardiac metal implant - You have had brain surgery or significant head trauma - You have recently received electroconvulsive therapy (ECT) or similar physical brain treatments - You have other psychiatric or neurological conditions that could interfere with results Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICENervio-X

An 8-channel TIS device developed by NEURODOME Corporation.


Locations(1)

Shanghai Pudong New Area Mental Health Center

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06461260


Related Trials